Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.

Salinger DH, Subramoney V, Everitt D, Nedelman JR.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00907-19. doi: 10.1128/AAC.00907-19. Print 2019 Oct.

2.

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.

Li H, Salinger DH, Everitt D, Li M, Del Parigi A, Mendel C, Nedelman JR.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00445-19. doi: 10.1128/AAC.00445-19. Print 2019 Oct.

3.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

4.

Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.

Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH.

J Clin Microbiol. 2016 May;54(5):1276-81. doi: 10.1128/JCM.03162-15. Epub 2016 Feb 24.

5.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.

Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.

PMID:
25795076
6.

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.

PMID:
25622149
7.

Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.

Winter H, Ginsberg A, Egizi E, Erondu N, Whitney K, Pauli E, Everitt D.

Antimicrob Agents Chemother. 2013 Nov;57(11):5516-20. doi: 10.1128/AAC.00798-13. Epub 2013 Aug 26.

8.

Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.

Winter H, Egizi E, Erondu N, Ginsberg A, Rouse DJ, Severynse-Stevens D, Pauli E, Everitt D.

Antimicrob Agents Chemother. 2013 Aug;57(8):3699-703. doi: 10.1128/AAC.02632-12. Epub 2013 May 20.

9.

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK.

Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0. Epub 2012 Jul 23.

PMID:
22828481
10.

G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling.

Morris GE, Nelson CP, Everitt D, Brighton PJ, Standen NB, Challiss RA, Willets JM.

Cardiovasc Res. 2011 Jan 1;89(1):193-203. doi: 10.1093/cvr/cvq249. Epub 2010 Aug 12.

11.

Endothelin-I and angiotensin II inhibit arterial voltage-gated K+ channels through different protein kinase C isoenzymes.

Rainbow RD, Norman RI, Everitt DE, Brignell JL, Davies NW, Standen NB.

Cardiovasc Res. 2009 Aug 1;83(3):493-500. doi: 10.1093/cvr/cvp143. Epub 2009 May 8.

PMID:
19429666
12.
13.

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.

Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, Zhu Y, Pendley CE, Graham MA, Mascelli MA.

Curr Med Res Opin. 2007 May;23(5):1081-92.

PMID:
17519075
14.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE.

J Clin Pharmacol. 2007 Mar;47(3):383-96.

PMID:
17322150
15.

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, Pendley CE, Cooper KD.

J Immunol. 2006 Oct 1;177(7):4917-26.

16.

A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.

Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T; Multiple Sclerosis Investigators.

Curr Med Res Opin. 2006 Sep;22(9):1671-8.

PMID:
16968570
17.

A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.

Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E.

J Rheumatol. 2006 May;33(5):847-53. Epub 2006 Apr 1.

PMID:
16583466
18.

A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.

Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA.

J Invest Dermatol. 2004 Dec;123(6):1037-44.

19.

Analysis and optimization of a diffuse photon optical tomography of turbid media

Everitt DL, Wei Sp, Zhu XD.

Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 2000 Aug;62(2 Pt B):2924-36.

PMID:
11088776
20.

Experimental determination of the boundary condition for diffuse photons in a homogeneous turbid medium

Everitt DL, Zhu T, Zhu HM, Zhu XD.

J Opt Soc Am A Opt Image Sci Vis. 2000 Jul;17(7):1284-7.

PMID:
10883981
21.

Rosiglitazone and hepatic failure.

Freid J, Everitt D, Boscia J.

Ann Intern Med. 2000 Jan 18;132(2):164. No abstract available.

PMID:
10644281
22.
23.

Inhibition of vascular K(ATP) channels by U-37883A: a comparison with cardiac and skeletal muscle.

Wellman GC, Barrett-Jolley R, Köppel H, Everitt D, Quayle JM.

Br J Pharmacol. 1999 Oct;128(4):909-16.

24.

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA.

Antimicrob Agents Chemother. 1999 May;43(5):1183-8.

25.

Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.

Piltz JR, Stone RA, Boike S, Everitt DE, Shusterman NH, Audet P, Zariffa N, Jorkasky DK.

J Ocul Pharmacol Ther. 1998 Jun;14(3):203-16.

PMID:
9671428
26.

Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.

Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK.

Clin Pharmacol Ther. 1998 Jun;63(6):617-22.

PMID:
9663175
27.

Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.

Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK.

J Clin Psychopharmacol. 1997 Dec;17(6):451-9.

PMID:
9408807
28.

Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension.

Everitt DE, Boike SC, Piltz-Seymour JR, VanCoevorden R, Audet P, Zariffa N, Jorkasky D.

J Clin Pharmacol. 1997 Apr;37(4):312-20.

PMID:
9115057
29.

Neomycin inhibits K+-induced force and Ca2+ channel current in rat arterial smooth muscle.

Langton PD, Farley R, Everitt DE.

Pflugers Arch. 1996 Nov-Dec;433(1-2):188-93.

PMID:
9019722
30.

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK.

J Infect Dis. 1996 Sep;174(3):463-9.

PMID:
8769601
31.

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Ruggieri EV, Bugelski PJ, Kaplan JM, Everitt D, Lipani J, Jorkasky DK, Boike SC, DeClement F, Moore FD Jr, Herzyk DJ.

J Clin Immunol. 1996 Mar;16(2):97-106.

PMID:
8690778
32.

The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.

Gurwitz JH, Everitt DE, Monane M, Glynn RJ, Choodnovskiy I, Beaudet MP, Avorn J.

J Gerontol A Biol Sci Med Sci. 1996 Mar;51(2):M74-9.

PMID:
8612107
33.

Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.

Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, Walker A.

Am J Med. 1995 Jul;99(1):48-54.

PMID:
7598142
34.

Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.

Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE, Brown LE, Rizzo SM, Nichols AI, Jorkasky DK.

J Clin Pharmacol. 1994 Nov;34(11):1098-108.

PMID:
7876402
35.

Patterns of glaucoma medication use in the elderly: 1980-1990.

Bohn RL, Glynn RJ, Gurwitz JH, Everitt DE, Gilden D, Avorn J.

J Glaucoma. 1994 Fall;3(3):259-64. No abstract available.

PMID:
19920606
36.

Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication.

Avorn J, Monane M, Everitt DE, Beers MH, Fields D.

Arch Intern Med. 1994 May 23;154(10):1113-7.

PMID:
7910451
37.

Adverse pulmonary effects of topical Beta blockers used in the treatment of glaucoma.

Avorn J, Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Everitt DE, Gilden D, Choodnovskiy I.

J Glaucoma. 1993 Fall;2(3):158-65.

PMID:
19920512
38.

Treatment for glaucoma: adherence by the elderly.

Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N, Avorn J.

Am J Public Health. 1993 May;83(5):711-6.

39.

Anticholinergic drug use and bowel function in nursing home patients.

Monane M, Avorn J, Beers MH, Everitt DE.

Arch Intern Med. 1993 Mar 8;153(5):633-8.

PMID:
8439226
40.

A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes.

Avorn J, Soumerai SB, Everitt DE, Ross-Degnan D, Beers MH, Sherman D, Salem-Schatz SR, Fields D.

N Engl J Med. 1992 Jul 16;327(3):168-73.

41.

Beta-blockers and depression. Evidence against an association.

Bright RA, Everitt DE.

JAMA. 1992 Apr 1;267(13):1783-7.

PMID:
1347572
42.

Resident behavior and staff distress in the nursing home.

Everitt DE, Fields DR, Soumerai SS, Avorn J.

J Am Geriatr Soc. 1991 Aug;39(8):792-8.

PMID:
2071810
43.
44.

Changing surgical antimicrobial prophylaxis practices through education targeted at senior department leaders.

Everitt DE, Soumerai SB, Avorn J, Klapholz H, Wessels M.

Infect Control Hosp Epidemiol. 1990 Nov;11(11):578-83.

PMID:
2124233
45.

Clinical decision-making in the evaluation and treatment of insomnia.

Everitt DE, Avorn J, Baker MW.

Am J Med. 1990 Sep;89(3):357-62. Erratum in: Am J Med 1990 Dec;89(6):838.

PMID:
2393038
46.

Pygmalion in the nursing home. The effects of caregiver expectations on patient outcomes.

Learman LA, Avorn J, Everitt DE, Rosenthal R.

J Am Geriatr Soc. 1990 Jul;38(7):797-803.

PMID:
2196306
47.

Systemic effects of medications used to treat glaucoma.

Everitt DE, Avorn J.

Ann Intern Med. 1990 Jan 15;112(2):120-5. Review.

PMID:
1967209
48.

Basic principles of prescribing for geriatric outpatients.

Carty MA, Everitt DE.

Geriatrics. 1989 Jun;44(6):85-8, 90-2, 97-8.

PMID:
2721971
49.

Medicaid data as a resource for epidemiologic studies: strengths and limitations.

Bright RA, Avorn J, Everitt DE.

J Clin Epidemiol. 1989;42(10):937-45.

PMID:
2681546
50.

Psychoactive medication use in intermediate-care facility residents.

Beers M, Avorn J, Soumerai SB, Everitt DE, Sherman DS, Salem S.

JAMA. 1988 Nov 25;260(20):3016-20.

PMID:
2903260

Supplemental Content

Loading ...
Support Center